Snapshot · AbbVie Inc. (ABBV)

Data as of 2026-10-18T09:50:49.979Z

Fundamentals check

Market cap

$504.4B

P/E (TTM)

80.4

Gross margin

71.5%

Net margin

9.8%

ROE

-136.5%

R&D / revenue

15.1%

Dividend yield

2.4%

FCF yield

3.6%

Latest dividend: $1.73/share (ex-date 2026-10-15, quarterly)

Summary

AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.

How it makes money

Revenue mix, latest fiscal year

• SKYRIZI30.2%
• RINVOQ14.3%
• H U M I R A7.8%
• Botox Therapeutic6.5%
• Vraylar6.2%
• Imbruvica4.9%

Recent Events

• 2026-10-17T08:00:20.000Zpositive

  AbbVie's Dividend Keeps Climbing. Is It Still a Buy for Income Investors?

  可能与股息增长及收益率变化相关，反映投资者对分红能力的关注。

  Source: 247wallst.com

• 2026-10-17T04:44:00.000Zpositive

  Forget High-Yield Traps: AbbVie Is the Dividend King to Buy and Hold Through Any Rate Cycle

  可能与股息定位和长期股息能力相关，传递持续分红的信号。

  Source: fool.com

• 2026-10-17T03:57:01.000Znegative

  AbbVie Inc. $ABBV Shares Sold by Banque Pictet & Cie SA

  可能与机构投资者减持相关，呈现负面信号。

  Source: defenseworld.net

• 2026-10-15T00:00:00.000Zneutral

  ABBV filed 8-K

  可能包含公司更新或业绩信息的披露，属常规事件。

  Source: SEC EDGAR

• 2026-10-14T00:00:00.000Zpositive

  Price move: ABBV rose 3.3%

  ABBV 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-10-05T14:49:00.000Zpositive

  Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

  可能与Epcoritamab联合治疗方案的PFS提升相关，对AbbVie组合策略有正向信号。

  Source: globenewswire.com

• 2026-08-18T00:00:00.000Zpositive

  Price move: ABBV rose 3.4%

  ABBV 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

Analyst view

Avg price target $299.5 from 12 analysts (last quarter)

Insider & Congress activity

Open-market trades only; grants and exercises excluded

• 2026-08-14SellDonoghoe Nicholas(officer: EVP, CHIEF BUS/STRAT OFFICER)32,710 shares

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。